Lakefront Biotherapeutics (GLPGF) Beginning Cash Balance (2019 - 2021)

Lakefront Biotherapeutics (GLPGF) has reported Beginning Cash Balance for 3 consecutive years, with $2.5 billion the latest figure, recorded in Q4 2021.

• On a quarterly basis, Beginning Cash Balance rose 10.45% year-over-year to $2.5 billion in Q4 2021; TTM through Dec 2021 was $2.5 billion, a 10.45% increase from a year earlier, with the FY2021 full-year figure at $2.5 billion, up 10.45% from the prior year.
• Beginning Cash Balance was $2.5 billion for Q4 2021 at Lakefront Biotherapeutics, down from $2.6 billion in the prior quarter.
• Over five years, Beginning Cash Balance peaked at $2.6 billion in Q2 2021 and troughed at $1.4 billion in Q4 2019.
• A 3-year average of $2.1 billion and a median of $2.2 billion in 2020 frame the typical range for Beginning Cash Balance.
• Across the five-year window, Beginning Cash Balance soared 55.35% in 2020 and grew 10.45% in 2021, its largest moves.
• Over 3 years, Beginning Cash Balance stood at $1.4 billion in 2019, then surged by 55.35% to $2.2 billion in 2020, then advanced by 10.45% to $2.5 billion in 2021.
• The last three Beginning Cash Balance figures came in at $2.5 billion (Q4 2021), $2.6 billion (Q2 2021), and $2.2 billion (Q4 2020), per Business Quant data.